Search

Displaying results 1531 - 1540 of 2674 in total
  1. Drug

    Alogliptin

    go.drugbank.com/drugs/DB06203
    ApprovedInvestigational

    FDA approved January 25, 2013.

  2. Drug

    Artesunate

    go.drugbank.com/drugs/DB09274
    ApprovedInvestigational

    [A203948] Artesunate was granted FDA approval on 26 May 2020.[L14099]

  3. Drug

    Dimethyl fumarate

    go.drugbank.com/drugs/DB08908
    ApprovedInvestigational

    [A253917] Prior to its FDA approval, dimethyl fumarate had been used in Germany for treatment of psoriasis.[A253917] … [L43752] Dimethyl fumarate is marketed under the brand name Tecfidera, and it was the third oral disease-modifying agent for multiple sclerosis approved by the FDA, following [fingolimod] and [teriflunomide

  4. Drug

    Tebentafusp

    go.drugbank.com/drugs/DB15283
    ApprovedInvestigational

    to be approved by the FDA. … [A244815] On January 26, 2022, tebentafusp was first approved by the FDA for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma.

  5. Drug

    Naltrexone

    go.drugbank.com/drugs/DB00704
    ApprovedInvestigationalVet approved

    The FDA has approved naltrexone for the treatment of alcohol dependence.

  6. Drug

    Vilazodone

    go.drugbank.com/drugs/DB06684
    ApprovedInvestigational

    Vilazodone was given FDA approval on January 21, 2011[L6046,A177622].

    Categories: Serotonin Receptor Agonists, Serotonin 5-HT1 Receptor Agonists
  7. Drug

    Acellular nerve allograft

    go.drugbank.com/drugs/DB30293
    ApprovedInvestigational

    Approved by the FDA under a Biologics License Application (BLA) as an acellular nerve scaffold for the treatment of adult and pediatric patients (aged ≥1 month) with sensory, mixed, and motor peripheral

  8. Drug

    Talarozole

    go.drugbank.com/drugs/DB13083
    Investigational

    Talarozole has been investigated for the treatment of Psoriasis and Cutaneous Inflammation.

  9. Drug

    Trastuzumab

    go.drugbank.com/drugs/DB00072
    ApprovedInvestigational

    Kanjinti (trastuzumab-anns)[L14135] and Hercessi[L52840] are other biosimilars approved by the FDA. In Canada, biosimilars ONTRUZANT[[L40303, L40308] and Adheroza[L52835] are approved. … In December 2017, FDA approved OGIVRI (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction

    Categories: HER2 Receptor Antagonists, HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
  10. Drug

    Drospirenone

    go.drugbank.com/drugs/DB01395
    ApprovedInvestigational

    [L7973] Most recently, it was approved by both Health Canada and the FDA in combination with [Estetrol] as an oral contraceptive therapy. … [A182543,A182552] In 2012, however, a safety statement by the FDA concluded that the increase in the risk of thromboembolism resulting from the use of drospirenone remains unclear, as studies regarding

    Categories: Mineralocorticoid Receptor Antagonists